공고 • Aug 13
Streamline Health Solutions, Inc.(NasdaqCM:STRM) dropped from NASDAQ Composite Index Streamline Health Solutions, Inc. has been dropped from the NASDAQ Composite Index 공고 • May 29
Hayes Management Consulting, Inc. entered into a definitive merger agreement to acquire Streamline Health Solutions, Inc. (NasdaqCM:STRM) for $23.1 million. Hayes Management Consulting, Inc. entered into a definitive merger agreement to acquire Streamline Health Solutions, Inc. (NasdaqCM:STRM) for $23.1 million on May 29, 2025. A cash consideration valued at $5.34 per share will be paid by Hayes Management Consulting, Inc. The all cash transaction is valued at approximately $37.4 million, including debt. Sell side termination fee is $9 million. The closing of the transaction is subject to certain customary closing conditions, including approval of the merger agreement by the Streamline stockholders. The transaction is not subject to a financing condition, and MDaudit intends to finance the transaction using a combination of cash on hand and available funds from existing credit facilities. The merger is expected to close during the third quarter of 2025. Cain Brothers acted as exclusive financial advisor to Streamline and rendered a fairness opinion to its Board of Directors, and David W. Ghegan of Troutman Pepper Locke LLP served as legal counsel to Streamline. Andrew J. Weidhaas and Rachel Frankeny of Goodwin Procter, LLP served as legal counsel to MDaudit. 공고 • May 03
Streamline Health Solutions, Inc. announced delayed annual 10-K filing On 05/02/2025, Streamline Health Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Apr 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Earnings have declined by 37% per year over the past 5 years. Market cap is less than US$10m (US$9.36m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Apr 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.28m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Earnings have declined by 37% per year over the past 5 years. Market cap is less than US$10m (US$8.28m market cap). Price Target Changed • Mar 16
Price target decreased by 40% to US$22.50 Down from US$37.50, the current price target is provided by 1 analyst. New target price is 633% above last closing price of US$3.07. Stock is down 61% over the past year. The company posted a net loss per share of US$4.96 last year. 공고 • Dec 17
Streamline Health Solutions, Inc. announced delayed 10-Q filing On 12/16/2024, Streamline Health Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공고 • Dec 10
Streamline Health Solutions, Inc. to Report Q3, 2025 Results on Dec 16, 2024 Streamline Health Solutions, Inc. announced that they will report Q3, 2025 results After-Market on Dec 16, 2024 New Risk • Sep 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.99m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (US$9.99m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$7.1m net loss next year). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Reported Earnings • Sep 13
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.047 loss per share (further deteriorated from US$0.045 loss in 2Q 2024). Revenue: US$4.48m (down 22% from 2Q 2024). Net loss: US$2.80m (loss widened 12% from 2Q 2024). Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. 공고 • Sep 05
Streamline Health Solutions, Inc. to Report Q2, 2025 Results on Sep 11, 2024 Streamline Health Solutions, Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Sep 11, 2024 Reported Earnings • Jun 13
First quarter 2025 earnings: EPS misses analyst expectations First quarter 2025 results: US$0.047 loss per share (improved from US$0.052 loss in 1Q 2024). Revenue: US$4.33m (down 19% from 1Q 2024). Net loss: US$2.74m (loss narrowed 5.6% from 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. New Risk • Jun 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.8m net loss in 2 years). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Market cap is less than US$100m (US$27.7m market cap). 공고 • Jun 06
Streamline Health Solutions, Inc. to Report Q1, 2025 Results on Jun 11, 2024 Streamline Health Solutions, Inc. announced that they will report Q1, 2025 results After-Market on Jun 11, 2024 공고 • May 16
Streamline Health Solutions, Inc., Annual General Meeting, Jun 13, 2024 Streamline Health Solutions, Inc., Annual General Meeting, Jun 13, 2024. New Risk • May 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.8m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (US$21.8m market cap). Reported Earnings • Apr 30
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: US$0.33 loss per share (further deteriorated from US$0.23 loss in FY 2023). Revenue: US$22.6m (down 9.2% from FY 2023). Net loss: US$18.7m (loss widened 64% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.3%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. New Risk • Apr 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$9.9m net loss next year). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (US$18.2m market cap). 공고 • Apr 23
Streamline Health Solutions, Inc. to Report Q4, 2024 Results on Apr 29, 2024 Streamline Health Solutions, Inc. announced that they will report Q4, 2024 results After-Market on Apr 29, 2024 Major Estimate Revision • Dec 21
Consensus EPS estimates fall by 86% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$24.1m to US$22.7m. Losses expected to increase from US$0.18 per share to US$0.34. Healthcare Services industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$1.25 unchanged from last update. Share price fell 6.0% to US$0.33 over the past week. Reported Earnings • Dec 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.21 loss per share (further deteriorated from US$0.066 loss in 3Q 2023). Revenue: US$6.13m (down 1.4% from 3Q 2023). Net loss: US$11.9m (loss widened 280% from 3Q 2023). Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. 공고 • Dec 14
Streamline Health Solutions, Inc. Announces Impairment Charges for the Three Months Ended October 31, 2023 Streamline Health Solutions, Inc. announced impairment charges for the three months ended October 31, 2023. For the quarter, the company reported Impairment of goodwill of $9,813,000 and Impairment of long-lived assets of $963,000. 공고 • Dec 07
Streamline Health Solutions, Inc. to Report Q3, 2024 Results on Dec 13, 2023 Streamline Health Solutions, Inc. announced that they will report Q3, 2024 results After-Market on Dec 13, 2023 공고 • Oct 29
Streamline Health Solutions, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price On October 24, 2023, Streamline Health Solutions, Inc. (the Company") received a letter from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market indicating that the closing bid price of the Company's common stock, par value $0.01 per share, has been below the minimum bid price of $1.00 per share for the previous 30 consecutive business days, which is required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement"). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has provided the Company with 180 calendar days, or until April 22, 2024, to regain compliance with the Bid Price Requirement. During this period, the Company's common stock will continue to trade uninterrupted on The Nasdaq Capital Market under the symbol STRM." To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 for a minimum of 10 consecutive business days at any time before April 22, 2024. If by April 22, 2024, the Company cannot demonstrate compliance with the Bid Price Requirement, it may be eligible for additional time, subject to meeting the continued listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Requirement. If the Company meets these requirements, the Company will have an additional 180 calendar days to comply in order for the Company's common stock to remain listed on The Nasdaq Capital Market. If the Company is not eligible for the second compliance period, then the Staff will provide notice that the Company's securities will be subject to delisting, which determination may be appealed to the Nasdaq Hearings Panel. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options if the closing bid price of the Company's common stock remains below $1.00 per share. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement, even if it maintains compliance with the other listing requirements. 공고 • Oct 18
Streamline Health Solutions, Inc. Announces CEO Changes Streamline Health Solutions, Inc. announced certain management changes and transitions in connection with the strategic restructuring. Effective October 13, 2023, Benjamin Stilwill has been appointed to the position of Chief Executive Officer of the Company. Mr. Stilwill will succeed Wyche T. “Tee” Green, III as Chief Executive Officer of the Company, with Mr. Green transitioning to the role of Executive Chairman at that time. Following his transition to the role of Executive Chairman, Mr. Green has agreed to forego a salary and will continue to serve as a director and as Chairman of the board of directors of the Company. Mr. Stilwill most recently served as Streamline’s President and, prior to that, as CEO of the Company’s eValuator business. Mr. Stilwill was instrumental in developing a world class client success organization within eValuator focused on maintaining key client relationships and establishing a portfolio of referenceable accounts. Mr. Stilwill joined Streamline in 2013 as a senior financial analyst and has held various senior roles across the organization. Prior to joining Streamline Health, Mr. Stilwill was a financial analyst in BMO Capital Markets’ M&A Practice. Mr. Stilwill holds an Executive MBA from Villanova University and a Bachelor of Arts degree in Economics from DePauw University. New Risk • Sep 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$7.3m net loss next year). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$49.9m market cap). New Risk • Sep 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 168% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 168% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$49.9m market cap). 공고 • Sep 07
Streamline Health Solutions, Inc. to Report Q2, 2024 Results on Sep 13, 2023 Streamline Health Solutions, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Sep 13, 2023 Reported Earnings • Jun 13
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: US$0.052 loss per share. Revenue: US$5.33m (down 10% from 1Q 2023). Net loss: US$2.90m (loss widened 4.1% from 1Q 2023). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 9.1%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US. 공고 • Jun 06
Streamline Health Solutions, Inc. to Report Q1, 2024 Results on Jun 12, 2023 Streamline Health Solutions, Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on Jun 12, 2023 공고 • May 12
Streamline Health Solutions, Inc., Annual General Meeting, Jun 15, 2023 Streamline Health Solutions, Inc., Annual General Meeting, Jun 15, 2023, at 10:00 US Eastern Standard Time. Agenda: To elect the five candidates nominated by company's board of directors to serve as directors until a successor is duly elected and qualified at the 2024 Annual Meeting of Stockholders or otherwise or until any earlier removal or resignation; to approve, on a non-binding advisory basis, the compensation of the named executive officers; to ratify the appointment of the firm of FORVIS, LLP to serve as the independent registered public accounting firm for fiscal year 2023; to approve an amendment to Streamline Health Solutions, Inc.’s Third Amended and Restated 2013 Stock Incentive Plan, to increase the number of shares of common stock available for issuance under the Third Amended 2013 Plan; and to consider any and all other business that may properly come before the meeting or any adjournment thereof. Reported Earnings • Apr 29
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$0.23 loss per share (further deteriorated from US$0.16 loss in FY 2022). Revenue: US$24.9m (up 43% from FY 2022). Net loss: US$11.4m (loss widened 65% from FY 2022). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. 공고 • Feb 16
Streamline Health Solutions, Inc. Provides Revenue Guidance for the Year Ended January 31, 2023 Streamline Health Solutions, Inc. provided revenue guidance for the year ended January 31, 2023. The company anticipates total revenues to be in the range of $24.9 million – $25.2 million, an increase of approximately 43% – 45% compared to $17.4 million during fiscal year 2021. Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Justin Ferayorni was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 15
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: US$0.066 loss per share (improved from US$0.096 loss in 3Q 2022). Revenue: US$6.22m (up 13% from 3Q 2022). Net loss: US$3.14m (loss narrowed 28% from 3Q 2022). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Price Target Changed • Nov 17
Price target increased to US$3.00 Up from US$2.75, the current price target is an average from 2 analysts. New target price is 72% above last closing price of US$1.74. Stock is up 3.0% over the past year. The company is forecast to post a net loss per share of US$0.23 next year compared to a net loss per share of US$0.16 last year. Reported Earnings • Sep 08
Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2023 results: US$0.069 loss per share (further deteriorated from US$0.002 loss in 2Q 2022). Revenue: US$5.99m (up 109% from 2Q 2022). Net loss: US$3.27m (loss widened US$3.20m from 2Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Major Estimate Revision • Sep 03
Consensus estimates of losses per share improve by 13% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from US$22.4m to US$24.2m. EPS estimate increased from -US$0.24 per share to -US$0.21 per share. Healthcare Services industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 4.4% to US$1.51 over the past week. Major Estimate Revision • Jun 16
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 revenue forecast increased from US$21.7m to US$22.4m. Forecast EPS reduced from -US$0.20 to -US$0.24 per share. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 17% to US$1.14 over the past week. Reported Earnings • Jun 10
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2023 results: US$0.059 loss per share. Revenue: US$5.94m (up 101% from 1Q 2022). Net loss: US$2.79m (loss widened 13% from 1Q 2022). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) missed analyst estimates by 9.1%. Over the next year, revenue is forecast to grow 10%, compared to a 17% growth forecast for the industry in the US. Reported Earnings • Apr 29
Full year 2022 earnings released: US$0.16 loss per share (vs US$0.16 loss in FY 2021) Full year 2022 results: US$0.16 loss per share (down from US$0.16 loss in FY 2021). Revenue: US$17.4m (up 53% from FY 2021). Net loss: US$6.92m (loss widened 44% from FY 2021). Over the next year, revenue is forecast to grow 24%, compared to a 20% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target increased to US$3.00 Up from US$2.75, the current price target is provided by 1 analyst. New target price is 114% above last closing price of US$1.40. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$0.22 next year compared to a net loss per share of US$0.16 last year. Price Target Changed • Apr 08
Price target increased to US$3.00 Up from US$2.75, the current price target is an average from 2 analysts. New target price is 92% above last closing price of US$1.56. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.23 next year compared to a net loss per share of US$0.16 last year. Major Estimate Revision • Dec 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$15.9m to US$16.5m. Forecast EPS reduced from -US$0.15 to -US$0.22 per share. Healthcare Services industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 7.6% to US$1.46 over the past week. Reported Earnings • Dec 10
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.096 loss per share (down from US$0.035 loss in 3Q 2021). Revenue: US$5.51m (up 109% from 3Q 2021). Net loss: US$4.38m (loss widened 310% from 3Q 2021). Revenue exceeded analyst estimates by 27%. Earnings per share (EPS) also surpassed analyst estimates by 100%. Earnings per share (EPS) surpassed analyst estimates by 100%. Over the next year, revenue is forecast to grow 31%, compared to a 22% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year. Price Target Changed • Dec 05
Price target increased to US$3.00 Up from US$2.75, the current price target is provided by 1 analyst. New target price is 117% above last closing price of US$1.38. Stock is down 24% over the past year. The company is forecast to post a net loss per share of US$0.16 next year compared to a net loss per share of US$0.16 last year. Reported Earnings • Sep 12
Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.039 loss in 2Q 2021) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2022 results: Revenue: US$2.87m (flat on 2Q 2021). Net loss: US$71.0k (loss narrowed 94% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Aug 18
Consensus revenue estimates increase to US$15.4m The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$12.9m to US$15.4m. Forecast losses expected to reduce from -US$0.20 to -US$0.18 per share. Healthcare Services industry in the US expected to see average net income growth of 24% next year. Consensus price target of US$2.75 unchanged from last update. Share price fell 3.2% to US$1.50 over the past week. Price Target Changed • Apr 26
Price target increased to US$3.00 Up from US$2.75, the current price target is provided by 1 analyst. New target price is 33% above last closing price of US$2.25. Stock is up 125% over the past year. Reported Earnings • Apr 26
Full year 2021 earnings released: US$0.16 loss per share (vs US$0.089 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: US$11.3m (down 45% from FY 2020). Net loss: US$4.80m (down 336% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 24
Full year 2021 earnings released: US$0.16 loss per share (vs US$0.089 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: US$11.3m (down 45% from FY 2020). Net loss: US$4.80m (down 336% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 10
Price target raised to US$3.00 Up from US$2.75, the current price target is provided by 1 analyst. The new target price is 58% above the current share price of US$1.90. As of last close, the stock is up 68% over the past year. 공고 • Feb 27
Streamline Health Solutions, Inc. has completed a Follow-on Equity Offering in the amount of $14 million. Streamline Health Solutions, Inc. has completed a Follow-on Equity Offering in the amount of $14 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,750,000
Price\Range: $1.6
Discount Per Security: $0.09212 
